Disease-modifying effects of sodium selenate in a model of drug-resistant, temporal lobe epilepsy
eLife · 2023
DOI: 10.7554/elife.78877 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2023. Verfasst von Pablo M Casillas-Espinosa und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, The Royal Melbourne Hospital, The University of Melbourne, Melbourne, Australia. Hauptthemen laut MEDLINE: Epilepsy, Temporal Lobe, Epilepsy, Status Epilepticus, Drug Resistant Epilepsy. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 128 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, National Health and Medical Research Council, University of Melbourne.
Abstract (Originalsprache)
There are no pharmacological disease-modifying treatments with an enduring effect to mitigate the seizures and comorbidities of established chronic temporal lobe epilepsy (TLE). This study aimed to evaluate for disease modifying effects of sodium selenate treatment in the chronically epileptic rat post-status epilepticus (SE) model of drug-resistant TLE. Wistar rats underwent kainic acid-induced SE or sham. Ten-weeks post-SE, animals received sodium selenate, levetiracetam, or vehicle subcutaneousinfusion continuously for 4 weeks. To evaluate the effects of the treatments, one week of continuous video-EEG was acquired before, during, and 4, 8 weeks post-treatment, followed by behavioral tests. Targeted and untargeted proteomics and metabolomics were performed on post-mortem brain tissue to identify potential pathways associated with modified disease outcomes. Telomere length was investigated as a novel surrogate marker of epilepsy disease severity in our current study. The results showed that sodium selenate treatment was associated with mitigation of measures of disease severity at 8 weeks post-treatment cessation; reducing the number of spontaneous seizures (p< 0.05), cognitive dysfunction (p< 0.05), and sensorimotor deficits (p< 0.01). Moreover, selenate treatment was associated with increased protein phosphatase 2A (PP2A) expression, reduced hyperphosphorylated tau, and reversed telomere length shortening (p< 0.05). Network medicine integration of multi-omics/pre-clinical outcomes identified protein-metabolite modules positively correlated with TLE. Our results provide evidence that treatment with sodium selenate results in a sustained disease-modifying effect in chronically epileptic rats in the post-KA SE model of TLE, including improved comorbid learning and memory deficits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, The Royal Melbourne Hospital, The University of Melbourne, Melbourne, Australia.
- Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia.
- Monash Proteomics & Metabolomics Facility and Monash Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
- Department of Neurology, The Alfred Hospital, Commercial Road,, Melbourne, Victoria, Australia.
ORCID-Profile: Pablo M Casillas-Espinosa, Anna Harutyunyan, Sandy R Shultz, Terence J O'Brien
Förderung
- CIHR
- National Health and Medical Research Council
- University of Melbourne
- CIHR Skin Research Training Centre
Zitieren
APA
Casillas-Espinosa, P. M., Anderson, A., Harutyunyan, A., Li, C., Lee, J., Braine, E. L., Brady, R. D., Sun, M., Huang, C., Barlow, C. K., Shah, A. D., Schittenhelm, R. B., Mychasiuk, R., Jones, N. C., Shultz, S. R., & O'Brien, T. J. (2023). Disease-modifying effects of sodium selenate in a model of drug-resistant, temporal lobe epilepsy. eLife. https://doi.org/10.7554/elife.78877
Vancouver
Casillas-Espinosa PM, Anderson A, Harutyunyan A, Li C, Lee J, Braine EL, et al. Disease-modifying effects of sodium selenate in a model of drug-resistant, temporal lobe epilepsy. eLife. 2023. doi:10.7554/elife.78877
BibTeX
@article{CasillasEspinosa2023,
author = {Casillas-Espinosa, Pablo M and Anderson, Alison and Harutyunyan, Anna and Li, Crystal and Lee, Jiyoon and Braine, Emma L and Brady, Rhys D and Sun, Mujun and Huang, Cheng and Barlow, Christopher K and Shah, Anup D and Schittenhelm, Ralf B and Mychasiuk, Richelle and Jones, Nigel C and Shultz, Sandy R and O'Brien, Terence J},
title = {Disease-modifying effects of sodium selenate in a model of drug-resistant, temporal lobe epilepsy},
journal = {eLife},
year = {2023},
doi = {10.7554/elife.78877}
}
EUVIMED